Efficacy and tolerability of LCM as add-on treatment in 17 outpatients (8 M, mean age 40.1) with drug-resistant epilepsy in antiepileptic polytherapy (6 patients with vagal stimulation) have been evaluated. Four patients discontinued LCM because of adverse events, such as diplopia, ataxia, vomiting, drowsiness, dizziness. Two of them who were receiving concomitant therapy with CBZ and OXC presented adverse events after increasing LCM from 200 mg/day to 400 mg/day, and the other 2 patients had been rapidly titrated (100 mg/week). The remaining patients with a slower titration showed a good safety profile. Despite limited observational period and small sample considered, it is possible to hypothesize that a rapid titration (100 mg/day) and/or an increase in dosage from 200 to 400 mg/day in patients already taking AEDs acting on sodium channels (particularly CBZ and OXC), may affect LCM tolerability with neurological adverse events such as ataxia and vertigo.
|Translated title of the contribution||Lacosamide: Tolerability and efficacy in early experiences of use in clinical practice|
|Number of pages||4|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - May 2012|
ASJC Scopus subject areas
- Clinical Neurology